Novartis AG's strong Q3 performance and optimistic outlook are further supported by key financial metrics from InvestingPro. The company's revenue growth of 8.92% over the last twelve months aligns with the reported 10% increase in sales, demonstrating consistent top-line expansion. This growth is complemented by a robust gross profit margin of 75.77%, indicating Novartis' ability to maintain pricing power and operational efficiency despite market pressures.